Last reviewed · How we verify
chemotherapy with LMWH - enoxaparin
chemotherapy with LMWH - enoxaparin is a Small molecule drug developed by CONKO-Studiengruppe. It is currently in Phase 2 development. Also known as: gemcitabine, cisplatin, folinic acid, 5-FU.
At a glance
| Generic name | chemotherapy with LMWH - enoxaparin |
|---|---|
| Also known as | gemcitabine, cisplatin, folinic acid, 5-FU |
| Sponsor | CONKO-Studiengruppe |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Prolonged Hypercoagulability Following Major Liver Resection for Malignancy (PHASE3)
- Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype (PHASE1, PHASE2)
- Taxotere-Enoxaparin-(ENOXA)-Study (PHASE3)
- Docetaxel and Liposomal Doxorubicin Chemotherapy With Enoxaparin in Patients With Advanced Pancreatic Cancer (PHASE2)
- A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer (PHASE3)
- Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer (PHASE2)
- Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement (PHASE3)
- Ischemia Driven Enoxaparin Therapy in ACS Presenting as Low Risk (IDEAL) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chemotherapy with LMWH - enoxaparin CI brief — competitive landscape report
- chemotherapy with LMWH - enoxaparin updates RSS · CI watch RSS
- CONKO-Studiengruppe portfolio CI
Frequently asked questions about chemotherapy with LMWH - enoxaparin
What is chemotherapy with LMWH - enoxaparin?
chemotherapy with LMWH - enoxaparin is a Small molecule drug developed by CONKO-Studiengruppe.
Who makes chemotherapy with LMWH - enoxaparin?
chemotherapy with LMWH - enoxaparin is developed by CONKO-Studiengruppe (see full CONKO-Studiengruppe pipeline at /company/conko-studiengruppe).
Is chemotherapy with LMWH - enoxaparin also known as anything else?
chemotherapy with LMWH - enoxaparin is also known as gemcitabine, cisplatin, folinic acid, 5-FU.
What development phase is chemotherapy with LMWH - enoxaparin in?
chemotherapy with LMWH - enoxaparin is in Phase 2.
Related
- Manufacturer: CONKO-Studiengruppe — full pipeline
- Also known as: gemcitabine, cisplatin, folinic acid, 5-FU